https://aximbiotech.com/axim-biotechnologies-completes-pre-clinical-drug-studies-on-new-compound-proving-tenfold-greater-inhibition-of-tumor-metastasis-than-parent-compound/2020-04-20T00:09:11-07:00https://aximbiotech.com/axim-biotechnologies-completes-acquisition-of-oncology-research-and-development-company-sapphire-biotech-inc/2020-04-20T00:10:27-07:00https://aximbiotech.com/axim-biotechnologies-acquiree-sapphire-biotech-inc-signs-license-agreement-to-exclusively-license-patent-rights-in-cancer-technology/2020-04-20T00:12:55-07:00https://aximbiotech.com/axim-biotechnologies-to-acquire-leading-oncology-research-and-development-company-sapphire-biotech-inc/2020-04-20T00:13:58-07:00https://aximbiotech.com/axim-biotechnologies-files-new-u-s-patent-application-for-water-soluble-cannabinoid-molecules/2020-05-01T14:21:00-07:00https://aximbiotech.com/axim-biotechnologies-announces-cultivation-agreement-to-establish-companys-first-domestic-industrial-hemp-source-begins-harvesting/2020-05-01T14:33:32-07:00https://aximbiotech.com/axim-biotechnologies-inc-signs-cannabinoid-product-supply-agreement-with-healthcare-company-for-clinical-trials-on-treatment-of-periodontitis/2020-05-01T14:44:23-07:00https://aximbiotech.com/axim-biotechnologies-issues-update-letter-to-shareholders/2020-05-13T10:16:19-07:00https://aximbiotech.com/axim-biotechnologies-files-for-patent-for-unique-biomarker-for-early-detection-of-cancer-in-blood/2020-07-17T15:12:29-07:00https://aximbiotech.com/axim-biotechnologies-expands-research-division-and-announces-dr-sergei-svarovsky-as-chief-scientific-officer-of-subsidiary-sapphire-biotech/2020-07-17T15:12:14-07:00https://aximbiotech.com/axim-biotechnologies-begins-pre-clinical-pharmacokinetic-animal-drug-studies-on-its-cancer-drug-compound-spx-1009/2020-07-17T15:11:57-07:00https://aximbiotech.com/axim-biotechnologies-appoints-dr-alim-seit-nebi-as-chief-technology-officer-of-subsidiary-sapphire-biotech/2020-07-17T15:11:41-07:00https://aximbiotech.com/axim-biotechnologies-unveils-first-in-class-covid-19-rapid-diagnostic-test-for-neutralizing-antibodies-and-files-pre-emergency-use-authorization-with-the-fda/2020-07-17T15:11:24-07:00https://aximbiotech.com/axim-biotechnologies-welcomes-former-secretary-of-veterans-affairs-peter-orourke-to-companys-board-of-directors/2020-07-21T09:38:39-07:00https://aximbiotech.com/axim-biotechnologies-releases-rapid-neucovix-test-results-showing-strong-agreement-with-covid-19-based-neutralization-tests/2020-07-22T19:31:18-07:00https://aximbiotech.com/first-in-class-covid-19-rapid-diagnostic-test-for-neutralizing-antibodies-could-serve-as-immunity-passport-for-vaccine-developers/2020-08-04T12:26:08-07:00https://aximbiotech.com/coronavirus-company-news-summary-bd-receives-additional-orders-for-177-million-injection-devices-axim-develops-covid-19-test-for-neutralising-antibodies/2020-08-04T12:29:03-07:00https://aximbiotech.com/axim-biotechnologies-unveils-rapid-test-for-neutralizing-antibodies-files-pre-eua-with-the-fda/2020-08-04T12:46:53-07:00https://aximbiotech.com/covid-fighters-rewarded-on-markets/2020-08-04T12:48:59-07:00https://aximbiotech.com/first-in-class-covid-19-rapid-diagnostic-test-for-neutralizing-antibodies-could-serve-as-immunity-passport-for-vaccine-developers-2/2020-08-04T15:45:04-07:00https://aximbiotech.com/bulls-take-charge-of-axim-biotechnologies-inc-otcmkts-axim/2020-10-20T13:20:47-07:00https://aximbiotech.com/axim-biotechnologies-applies-for-fda-emergency-use-approval-eua-for-high-throughput-patent-pending-neutralizing-antibody-diagnostic-test-for-covid-19/2020-08-04T23:40:50-07:00https://aximbiotech.com/sapphire-biotech-subsidiary-of-axim-biotechnologies-awarded-prestigious-phase-i-small-business-innovation-research-grant-by-national-cancer-institute/2020-08-10T16:51:01-07:00https://aximbiotech.com/axim-biotechnologies-signs-exclusive-licensing-manufacturing-and-distribution-agreement-for-high-volume-production-of-the-covid-19-rapid-neutralizing-antibody-test/2020-08-23T19:38:36-07:00https://aximbiotech.com/axim-biotechnologies-files-emergency-use-authorization-with-the-fda-for-first-in-class-covid-19-rapid-diagnostic-test-for-neutralizing-antibodies/2020-09-16T09:15:29-07:00https://aximbiotech.com/axim-biotechnologies-receives-notice-of-u-s-patent-allowance-for-proprietary-compounds-and-methods-targeting-tumor-metastasis-through-qsox1/2020-09-22T09:55:03-07:00https://aximbiotech.com/axim-biotechnologies-files-patent-for-worlds-first-face-mask-designed-to-capture-sars-cov-2-covid-19/2020-09-29T16:32:52-07:00https://aximbiotech.com/axim-biotechnologies-files-patent-for-virus-binding-recombinant-protein-for-sars-cov-2-covid-19-and-begins-manufacturing/2020-09-29T22:52:40-07:00https://aximbiotech.com/first-in-class-rapid-diagnostic-test-measures-covid-19-neutralizing-antibodies-in-plasma-and-serum/2020-10-20T13:28:43-07:00https://aximbiotech.com/making-a-better-facemask-axim-biotech-looks-to-be-a-leader-protecting-people-from-covid-19/2020-10-20T13:34:07-07:00https://aximbiotech.com/axim-biotechnologies-files-eua-with-fda-for-covid-19-rapid-diagnostic-test-for-neutralising-antibodies/2020-10-20T13:37:47-07:00https://aximbiotech.com/a-face-mask-coated-in-a-biological-mousetrap-for-the-virus-just-one-of-axims-inventions/2020-10-20T13:44:53-07:00https://aximbiotech.com/bioworld-news-to-note-for-sept-16-2020/2020-10-20T13:44:21-07:00https://aximbiotech.com/coronavirus-company-news-summary-color-receives-eua-for-covid-19-self-collection-kit-vivera-pharmaceuticals-launches-biozone-device/2020-10-20T13:46:59-07:00https://aximbiotech.com/worlds-first-face-mask-designed-to-capture-and-deactivate-sars-cov-2-could-lower-covid-19-infection-rate/2020-10-20T13:50:05-07:00https://aximbiotech.com/axim-biotechnologies-issues-update-letter-to-shareholders-2020/2020-10-27T21:57:11-07:00https://aximbiotech.com/axim-biotechnologies-applauds-vaccine-producers-highlights-need-for-rapid-antibody-testing-to-ensure-immunity/2020-11-10T10:16:10-08:00https://aximbiotech.com/research-and-development-company-addresses-covid-19-testing-and-cancer-care/2020-11-24T12:29:13-08:00https://aximbiotech.com/axim-biotechnologies-develops-elisa-based-neutralizing-antibody-diagnostic-test-for-covid-19-and-applies-for-patent-companys-fourth-covid-19-test-focused-patent-application/2020-12-02T23:53:13-08:00https://aximbiotech.com/axim-biotechnologies-to-present-at-the-13th-annual-ld-micro-main-event-investor-conference-on-monday-december-14/2020-12-15T22:18:12-08:00https://aximbiotech.com/axim-biotechnologies-completes-successful-covid-19-live-virus-test-and-files-amended-eua-for-portable-10-minute-rapid-diagnostic-test-for-neutralizing-antibodies/2020-12-15T22:22:23-08:00https://aximbiotech.com/axim-biotechnologies-releases-preprint-manuscript-describing-the-development-of-companys-rapid-point-of-care-test-that-measures-covid-19-neutralizing-antibodies/2021-01-10T23:06:53-08:00https://aximbiotech.com/axim-biotechnologies-begins-clinical-trials-of-its-immunopass-rapid-diagnostic-test-with-vaccine-recipients/2021-02-03T10:20:00-08:00https://aximbiotech.com/axim-biotechnologies-successfully-completes-point-of-care-clinical-trials-on-its-rapid-covid-19-neutralizing-antibody-test/2021-03-08T08:54:55-08:00https://aximbiotech.com/axim-biotechnologies-manufacturing-partner-empowered-diagnostics-files-emergency-use-authorization/2021-03-23T18:13:24-07:00https://aximbiotech.com/coronavirus-company-news-summary-axim-develops-elisa-based-neutralising-antibody-diagnostic-test-for-covid-19-ixlayer-and-cic-health-partner-to-expand-covid-testing-in-us-schools-a/2021-03-25T16:38:42-07:00https://aximbiotech.com/bioworld-others-news-note-for-dec-3/2021-03-25T16:44:33-07:00https://aximbiotech.com/new-elisa-based-covid-19-test-detects-and-ranks-sars-cov-2-neutralizing-antibodies-by-their-potency/2021-03-25T16:38:33-07:00https://aximbiotech.com/axim-files-amended-eua-for-diagnostic-test-for-covid-19-neutralizing-antibodies/2021-03-25T16:38:25-07:00https://aximbiotech.com/fda-authorizes-lateral-flow-antigen-test-as-first-otc-fully-at-home-test-for-covid-19/2021-03-25T16:38:17-07:00https://aximbiotech.com/tests-for-the-test-makers/2021-03-25T16:37:49-07:00https://aximbiotech.com/axim-biotechnologies-begins-trials-on-immunopass-rapid-diagnostic-test/2021-03-25T16:37:39-07:00https://aximbiotech.com/axim-biotechnologies-inc-covid-19-research/2021-03-25T16:37:30-07:00https://aximbiotech.com/whats-a-vaccine-passport-and-do-you-need-one/2021-03-25T16:36:08-07:00https://aximbiotech.com/axim-completes-point-of-care-trials-for-immunopass-covid-19-test/2021-03-25T16:37:12-07:00https://aximbiotech.com/beating-the-covid-19-crisis-the-role-of-vaccine-boosters/2021-03-25T16:37:01-07:00https://aximbiotech.com/what-is-a-covid-19-immunity-passport-and-why-is-it-better-than-a-vaccine-passport/2021-03-25T16:35:59-07:00https://aximbiotech.com/axim-partner-empowered-files-eua-with-fda-for-use-of-rapid-covid-19-neutralizing-antibody-test/2021-03-25T16:35:50-07:00https://aximbiotech.com/axim-biotechnologies-successfully-completes-point-of-care-clinical-trials-on-its-rapid-covid-19-neutralizing-antibody-test-nsmedical/2021-03-25T16:36:51-07:00https://aximbiotech.com/neutralizing-antibodies-and-covid-19-vaccines/2021-03-25T16:37:22-07:00https://aximbiotech.com/anew-test-looks-to-monitor-antibody-levels-after-covid-19-vaccine-shotaxim-partner-empowered-files-eua-with-fda-for-use-of-rapid-covid-19-neutralizing-antibody-test-thedenverchannel/2022-04-11T14:27:25-07:00https://aximbiotech.com/axim-biotechnologies-introduces-diagnostics-to-measure-immunity-against-emerging-sars-cov-2-variants/2021-05-18T15:42:33-07:00https://aximbiotech.com/axim-biotechnologies-manufacturing-partner-empowered-diagnostics-files-for-approval-for-use-of-rapid-covid-19-neutralizing-antibody-test-in-whole-blood-at-point-of-care-locations-in-can/2021-05-18T15:43:44-07:00https://aximbiotech.com/axim-biotechnologies-completes-pre-clinical-drug-studies-on-spx-1009-compound-proving-suppression-of-melanoma-cells/2021-08-03T08:29:23-07:00https://aximbiotech.com/axim-biotechnologies-to-acquire-technology-including-two-fda-cleared-510ks-for-diagnostic-testing-of-dry-eye-disease/2021-08-03T08:30:27-07:00https://aximbiotech.com/axim-biotechnologies-manufacturing-partner-empowered-diagnostics-files-amended-emergency-use-authorization-with-fda-for-its-rapid-covid-19-neutralizing-antibody-test-in-whole-blood-at-p/2021-08-30T07:55:39-07:00https://aximbiotech.com/axim-biotech-appoints-ophthalmic-industry-veteran-jeff-busby-as-senior-vp-business-development/2021-09-15T08:21:49-07:00https://aximbiotech.com/axim-biotechnologies-appoints-joseph-tauber-md-chief-medical-officer-and-chairman-of-its-medical-advisory-board/2021-09-22T10:58:25-07:00https://aximbiotech.com/axim-biotechnologies-appoints-senior-ded-expert-dr-laura-periman-to-its-medical-advisory-board/2021-10-05T09:12:21-07:00https://aximbiotech.com/axim-biotechnologies-appoints-leading-us-ophthalmic-surgeon-and-researcher-dr-henry-d-perry-to-its-medical-advisory-board/2021-10-11T13:33:06-07:00https://aximbiotech.com/axim-biotechnologies-develops-next-generation-of-its-rapid-neutralizing-antibody-test-for-covid-19/2021-10-12T09:08:38-07:00https://aximbiotech.com/axim-biotechnologies-appoints-dry-eye-disease-expert-and-accomplished-optometrist-dr-kelly-k-nichols-to-its-medical-advisory-board/2021-10-20T11:04:45-07:00https://aximbiotech.com/axim-biotechnologies-appoints-clinical-research-and-ded-expert-dr-michael-e-stern-to-its-medical-advisory-board/2021-11-02T09:40:21-07:00https://aximbiotech.com/axim-biotechnologies-development-of-rapid-test-for-covid-19-neutralizing-antibodies-is-cited-to-demonstrate-over-90-sensitivity-and-100-specificity/2021-11-09T08:15:03-08:00https://aximbiotech.com/axim-biotechnologies-partners-with-arizona-state-university-to-determine-antibody-levels-against-covid-19/2021-11-16T10:59:10-08:00https://aximbiotech.com/axim-biotechnologies-applauds-fdas-recent-covid-19-test-policies-to-support-rapid-neutralizing-antibody-tests/2021-11-18T08:36:37-08:00https://aximbiotech.com/cdc-publishes-axim-biotechnologies-sponsored-study-on-covid-19-neutralizing-antibodies/2021-12-21T08:12:32-08:00https://aximbiotech.com/axim-biotech-announces-new-milestones-in-preparation-of-dry-eye-disease-diagnostics-launch/2022-02-15T09:26:49-08:00https://aximbiotech.com/axim-biotech-launches-for-research-use-only-sales-for-its-covid-19-neutralizing-antibody-test/2022-03-07T08:57:08-08:00https://aximbiotech.com/axim-biotech-develops-rapid-quantitative-tear-test-for-mmp-9-an-inflammatory-biomarker-of-dry-eye-disease/2022-03-08T11:38:40-08:00https://aximbiotech.com/axim-biotech-develops-rapid-quantitative-tear-test-for-mmp-9-an-inflammatory-biomarker-for-ded/2022-05-18T15:42:34-07:00https://aximbiotech.com/axim-biotechnologies-ceo-issues-letter-to-shareholders/2022-05-18T15:43:46-07:00https://aximbiotech.com/axim-develops-quantitative-rapid-diagnostic-test-for-lacritin-now-boasts-four-dry-eye-disease-point-of-care-biomarker-tests/2022-05-18T15:43:21-07:00https://aximbiotech.com/axim-biotechnologies-develops-novel-tear-sample-collector-system-files-patent-application/2022-05-18T15:42:57-07:00https://aximbiotech.com/axim-biotechnologies-completes-optimization-of-only-fda-cleared-ige-rapid-diagnostics-test-in-house-manufacturing-lowers-cost-and-eliminates-supply-chain-expenditures/2022-06-02T08:31:28-07:00https://aximbiotech.com/axim-launches-new-eye-care-website-establishes-platform-for-commercialization/2022-06-02T08:33:48-07:00https://aximbiotech.com/will-this-dry-eye-rapid-test-prove-to-be-a-rapid-success/2022-07-11T10:27:45-07:00https://aximbiotech.com/axim-biotechnologies-publishes-study-highlighting-neutralizing-antibody-levels-of-poor-vaccine-responders-with-a-third-covid-19-vaccine-dose/2022-07-12T09:40:09-07:00https://aximbiotech.com/axim-biotechnologies-celebrates-feature-on-the-vision-is-more-than-20-20-podcast/2022-07-21T10:16:41-07:00https://aximbiotech.com/perform-a-pre-fit-ocular-surface-evaluation/2022-07-25T15:34:35-07:00https://aximbiotech.com/axim-biotechnologies-signs-exclusive-global-commercialization-agreement-with-versea-ophthalmics-for-distribution-and-sales-of-novel-ophthalmic-diagnostics-solutions/2022-09-19T09:24:34-07:00https://aximbiotech.com/axim-biotechnologies-point-of-care-diagnostic-test-platform-sales-commence-with-versea-ophthalmics-commercial-launch-at-aao-2022/2022-11-01T11:14:22-07:00https://aximbiotech.com/axim-biotechnologies-receives-initial-order-for-diagnostic-solutions-as-exclusive-partner-versea-ophthalmics-commences-initial-commercial-launch/2022-11-01T11:15:01-07:00https://aximbiotech.com/axim-biotechnologies-commercial-partner-versea-ophthalmics-highlights-benefits-of-axims-eye-diagnostic-solutions/2022-12-06T14:04:36-08:00https://aximbiotech.com/axim-biotechnologies-develops-novel-dual-ige-mmp-9-rapid-ophthalmological-diagnostic-test-files-provisional-patent/2022-12-13T11:52:29-08:00https://aximbiotech.com/axim-biotechnologies-ceo-issues-letter-to-shareholders-2/2023-01-09T14:42:59-08:00https://aximbiotech.com/axim-biotechnologies-files-patent-on-fentanyl-neutralizing-antibody-test-applies-for-dea-license-to-work-with-controlled-substance/2023-01-17T09:59:28-08:00https://aximbiotech.com/axim-biotechnologies-files-provisional-patent-on-novel-methodology-for-use-in-optical-diagnostic-assay-manufacturing/2023-03-14T09:44:47-07:00https://aximbiotech.com/axim-biotechnologies-commences-commercial-manufacturing-of-fda-cleared-proprietary-ocular-diagnostic-assays/2023-04-11T06:18:20-07:00https://aximbiotech.com/axim-biotechnologies-appoints-kurt-phinney-as-chief-operating-officer-to-drive-scaling-and-optimization-of-manufacturing-unit/2023-05-23T09:42:30-07:00https://aximbiotech.com/axim-biotechnologies-starts-shipping-revenue-generating-ige-diagnostic-validation-assays-to-customers-nationwide/2023-07-12T09:26:42-07:00https://aximbiotech.com/versea-ophthalmics-commences-phase-1-launch-of-novel-tear-based-point-of-care-t-poc-quantitative-testing-platform/2023-07-26T12:28:18-07:00https://aximbiotech.com/axim-biotechnologies-receives-notice-of-u-s-patent-allowance-for-three-separate-patents-including-its-rapid-point-of-care-neutralizing-antibody-test/2023-08-01T08:34:49-07:00https://aximbiotech.com/axim-biotechnologies-partners-with-leading-diagnostic-manufacturer-auer-precision-to-scale-assay-production/2023-12-20T06:34:32-08:00https://aximbiotech.com/axim-biotechnologies-tear-based-testing-platform-continues-to-gain-traction-after-successful-clinical-validation/2024-03-26T13:34:21-07:00https://aximbiotech.com/video-axim-biotechnologies-ceo-presents-at-benzinga-virtual-healthcare-summit-2024/2024-03-27T09:25:04-07:00https://aximbiotech.com/axim-biotechnologies-receives-medical-device-manufacturing-license/2024-05-29T06:57:52-07:00https://aximbiotech.com/axim-biotechnologies-files-pre-submission-with-fda-for-clia-waiver-pathway-on-lactoferrin-point-of-care-diagnostic-test/2025-06-24T10:59:59-07:00https://aximbiotech.com/axim-biotechnologies-inc-announces-exclusive-distribution-agreement-with-visionplus-corp-for-tearscan-lactoferrin-and-ige-diagnostic-tests-in-south-korea/2025-10-22T16:05:27-07:00https://aximbiotech.com/axim-biotechnologies-announces-exclusive-latin-america-license-distribution-agreement-with-jk-medical-for-tearscanr-ocular-diagnostic-tests/2025-11-18T07:58:31-08:00https://aximbiotech.com/axim-biotechnologies-engages-624-advisors-owned-and-managed-by-dr-alan-j-touch-innovator-and-global-regulatory-leader-as-chief-medical-regulatory-affairs-advisor/2026-01-27T10:16:50-08:00https://aximbiotech.com/axim-biotechnologies-inc-and-medical-marijuana-inc-enter-into-strategic-alliance-to-research-and-develop-applications-and-uses-of-patent-for-water-soluble-cannabinoids/2026-01-29T07:04:32-08:00